Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease
21 februari 2016 uppdaterad av: Galapagos NV
Double-Blind, Randomized, Placebo-Controlled, Multi-Centre Study to Investigate the Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease With Evidence of Mucosal Ulceration
- 180 patients suffering from active Crohn's disease with evidence of mucosal ulceration will be evaluated for improvement of disease activity (efficacy) when taking GLPG0634 or matching placebo once daily for 20 weeks in addition to their stable background treatment.
- During the course of the study, patients will also be examined for any side effects that may occur (safety and tolerability), and the amount of GLPG0634 present in the blood (Pharmacokinetics) as well as the effects of GLPG0634 on disease- and mechanism of action-related parameters in the blood and stool (Pharmacodynamics) will be determined. Also, the effects GLPG0634 administration on subjects' quality of life will be evaluated.
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Detaljerad beskrivning
- 180 patients suffering from active Crohn's disease with evidence of mucosal ulceration will be evaluated when taking GLPG0634 or matching placebo once daily in addition to their stable background treatment. The population will include 50% anti-TNF naïve patients and 50% of subjects previously exposed to anti-TNF.
- The study will consist of 2 parts, with total treatment duration of 20 weeks. Randomisation in Part 1 will be stratified according to subject's previous anti-TNF exposure, C-reactive protein (CRP) level at Screening and oral corticosteroid use at Day -1. However, at Week 10, subjects will be re-randomized automatically and stratified according to the subject's clinical response (reduction of Crohn's Disease Activity Index (CDAI) of 100 points), previous anti-TNF exposure and corticosteroid use at Day -1 to receive GLPG0634 200 mg q.d., 100 mg q.d. doses, or matching placebo q.d. in a blinded fashion. In Part 2, all will continue the study until Week 20.
- As efficacy parameters, the ability to achieve clinical response or remission, endoscopic response & remission as well as mucosal healing with GLPG0634 given once daily compared to placebo will be evaluated after 10 weeks of treatment. In subjects who achieved clinical remission at Week 10, maintenance of the remission will be assessed during Part 2 of the study.
- During the course of the study, patients will also be examined for any side effects that may occur (safety and tolerability), and the amount of GLPG0634 present in the blood (Pharmacokinetics) as well as the effects of GLPG0634 on disease- and mechanism of action-related parameters in the blood and stool (Pharmacodynamics) will be determined. Also, the effects of different doses and dose regimens of GLPG0634 administration on subjects' quality of life will be evaluated.
Studietyp
Interventionell
Inskrivning (Faktisk)
175
Fas
- Fas 2
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
-
Brussels, Belgien
- St. Pierre University Hospital Center
-
Brussels, Belgien
- University Hospital Saint Luc
-
Ghent, Belgien
- University Hospital Ghent
-
Leuven, Belgien
- University Hospitals Leuven
-
Liege, Belgien
- CHR de la Citadelle
-
Liege, Belgien
- Clinic Saint Joseph
-
-
-
-
-
Clermont-Ferrand, Frankrike
- Hospital Gabriel Montpied
-
Clichy, Frankrike
- Beaujon Hospital
-
Dijon, Frankrike
- Dijon University Hospital Center
-
Grenoble, Frankrike
- Hospital Michallon
-
Lille, Frankrike
- Lille Regional University Hospital Center
-
Marseille, Frankrike
- North Hospital
-
Nice, Frankrike
- Archet Hospital
-
Saint Etienne, Frankrike
- Saint Etienne University Hospital Center
-
-
-
-
-
Bydgoszcz, Polen
- Jan Biziel University Hospital #2
-
Lodz, Polen
- Saint Family Hospital Medical Center
-
Tychy, Polen
- H-T. Medical Center
-
Warsaw, Polen
- Maternal, Pediatric and Adolescent Healtcare Centre, Gastroenterology Diagnostic Facility for Adults
-
Warsaw, Polen
- Vivamed
-
Warsaw, Polen
- Clinical Hospital of Ministry of Internal Affairs and Administration
-
Wroclaw, Polen
- Active Health Center
-
-
-
-
-
Bucharest, Rumänien
- Colentina Clinical Hospital
-
Bucharest, Rumänien
- Fundeni Clinical Institute
-
Cluj-Napoca, Rumänien
- Medical Center for Gastroenterology
-
Timisoara, Rumänien
- Center for Gastroenterology, Ltd
-
-
-
-
-
Barnaul, Ryska Federationen
- Territorial Clinical Hospital
-
Kazan, Ryska Federationen
- State Medical University
-
Krasnoyarsk, Ryska Federationen
- Territorial Clinical Hospital
-
Moscow, Ryska Federationen
- City Clinical Hospital #24
-
Moscow, Ryska Federationen
- A.N. Ryzhikh State Research Center for Coloproctology
-
Moscow, Ryska Federationen
- Moscow Clinical Research Center
-
Moscow, Ryska Federationen
- Vladimirsky Regional Clinical Research Institute
-
Nizhny Novgorod, Ryska Federationen
- Semashko Nizhny Novgorod Regional Clinical Hospital
-
Novosibirsk, Ryska Federationen
- City Clinical Hospital #12
-
Saint Petersburg, Ryska Federationen
- City Clinical Hospital #31
-
Saint Petersburg, Ryska Federationen
- First Pavlov State Medical University
-
Saint Petersburg, Ryska Federationen
- Mechnikov North-Western State Medical University
-
Saint Petersburg, Ryska Federationen
- St. Elizabeth City Hospital
-
-
-
-
-
Birmingham, Storbritannien
- Queen Elizabeth Hospital
-
Bournemouth, Storbritannien
- Royal Bournemouth Hospital
-
Harrow, Storbritannien
- St Mark's Hospital
-
Manchester, Storbritannien
- Manchester Royal Infirmary
-
-
-
-
-
Hradec Kralove, Tjeckien
- Hepato-Gastroenterology HK Ltd.
-
Olomouc, Tjeckien
- University Hospital Olomouc
-
Pilsen, Tjeckien
- Outpatient Clinic of Internal Medicine and Gastroenterology
-
Prague, Tjeckien
- Institute of clinical and experimental medicine
-
Usti nad Labem, Tjeckien
- Masaryk's Hospital Usti Nad Labem
-
Znojmo, Tjeckien
- Hospital Znojmo
-
-
-
-
-
Berlin, Tyskland
- DRK Clinics Berlin Westend
-
Frankfurt-am-Main, Tyskland
- Interdisciplinary Crohn Colitis Center Rhein Main
-
Hamburg, Tyskland
- Asklepios West Hospital Hamburg
-
Jena, Tyskland
- University Hospital Jena
-
Kiel, Tyskland
- University Hospital Schleswig-Holstein
-
Magdeburg, Tyskland
- University Hospital Magdeburg
-
Minden, Tyskland
- Gastroenterology Group Practice Minden
-
Oldenburg, Tyskland
- Internal Medicine Group Practice Oldenburg
-
-
-
-
-
Balatonfured, Ungern
- Drug Research Center Ltd.
-
Budapest, Ungern
- Semmelweis University
-
Budapest, Ungern
- ClinExpert Medical Center
-
Budapest, Ungern
- Szent Margit Hospital
-
Debrecen, Ungern
- University of Debrecen, Medical and Health Science Center
-
Gyula, Ungern
- Bekes County Pandy Kalman Hospital
-
Szekszard, Ungern
- Tolna County Balassa Janos Hospital
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år till 75 år (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- Male or female subjects between 18 and 75 years
- Documented history of ileal, colonic, or ileocolonic CD
- CDAI score ≥ 220 to ≤ 450
- Evidence of active inflammation as demonstrated by endoscopic confirmation of active disease
- Subjects previously not exposed to anti-TNF treatment (TNF-naïve) or subjects previously exposed to anti-TNF therapy at a registered dose, that has been discontinued at least 8 weeks prior to Screening and deemed by the treating physician as a primary or secondary non-responder or intolerant (TNF-experienced)
- Continuation of concurrent treatment with oral steroids (≤30 mg prednisolone eq/day), mesalazine, olsalazine, CD-related antibiotics and probiotics at stable dose is allowed
- Previous exposure to immunomodulators is permitted, but must be discontinued
- Haematology and biochemistry lab parameters within predefined ranges as stated in the protocol
Exclusion Criteria:
- Diagnosis of indeterminate colitis, ulcerative colitis (UC), or clinical findings suggestive of UC
- Stoma, gastric or ileoanal pouch, procto- or total colectomy, symptomatic stenosis or obstructive strictures, history of bowel perforation, (suspected) abscess; actively draining fistulae
- Subject who has had surgical bowel resections within the past 6 months, short bowel syndrome or is receiving tube feeding, defined formula diets, or parenteral alimentation
- Subject with positive Clostridium difficile toxin stool assay or evidence of any other gastrointestinal infection
- Subject who has received non-permitted IBD therapies within specified timeframes, depending on the medication, as stated in the protocol
- Subject with a (previous history of) dysplasia of the gastrointestinal tract
- Concurrent gastro-intestinal malignancy or a history of cancer elsewhere
- History of lymphoproliferative disease
- Known active infection of any kind, current therapy for chronic infection or history of specific infections as stated in the protocol
- Subject who is pregnant, lactating or not willing to maintain highly effective birth control methods during the course of the study and 12 weeks thereafter
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: GLPG0634 200 mg QD
2 tablets of 100 mg GLPG0634 in the morning
|
100 mg oral tablet, intake once daily for 20 weeks
Andra namn:
|
|
Experimentell: GLPG0634 100 mg QD
1 tablet of 100 mg GLPG0634 and 1 placebo tablet in the morning
|
100 mg oral tablet, intake once daily for 20 weeks
Andra namn:
placebo oral tablets, intake once daily for 20 weeks
Andra namn:
|
|
Placebo-jämförare: Placebo QD
2 placebo tablets in the morning
|
placebo oral tablets, intake once daily for 20 weeks
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Percentage of subjects achieving clinical remission at Week 10
Tidsram: Week 10
|
Percentage of subjects achieving clinical remission as defined by a Crohn's Disease Activity Index score < 150 points
|
Week 10
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Percentage of subjects achieving clinical remission
Tidsram: Up to Week 20
|
Percentage of subjects achieving clinical remission as defined by a Crohn's Disease Activity Index score < 150 points, assessed at every visit
|
Up to Week 20
|
|
Percentage of subjects achieving clinical response
Tidsram: Up to Week 20
|
Percentage of subjects achieving clinical response as defined by a decrease in Crohn's Disease Activity Index score of at least 100 points, assessed at every visit
|
Up to Week 20
|
|
Percentage of subjects achieving endoscopic remission at Week 10
Tidsram: Week 10
|
Percentage of subjects achieving endoscopic remission as defined by a reduction of Simplified Endoscopy Score for Crohn's Disease (SES-CD) score ≤ 4, with ulcerated surface subscore no greater than 1 in any segment at Week 10
|
Week 10
|
|
Percentage of subjects achieving endoscopic response at Week 10
Tidsram: Week 10
|
Percentage of subjects achieving endoscopic response as defined by a reduction of Simplified Endoscopy Score for Crohn's Disease (SES-CD) score by at least 50% from Screening at Week 10
|
Week 10
|
|
Percentage of subjects achieving mucosal healing at Week 10
Tidsram: Week 10
|
Percentage of subjects achieving mucosal healing as defined by a Simplified Endoscopy Score for Crohn's Disease (SES-CD) score equal to 0 at Week 10
|
Week 10
|
|
Change from Baseline in Crohn's Disease Activity Index score
Tidsram: Up to Week 20
|
Change from Baseline in Crohn's Disease Activity Index score, assessed at every visit
|
Up to Week 20
|
|
Change from Screening in endoscopic score
Tidsram: Week 10
|
Change from Screening in endoscopic Simplified Endoscopy Score for Crohn's Disease (SES-CD) score at Week 10
|
Week 10
|
|
Change from Screening in histopathology biopsy score
Tidsram: Week 10
|
Change from Screening in histopathology biopsy score at Week 10
|
Week 10
|
|
Change from Baseline in Subjects' Quality of Life (based on the Inflammatory Bowel Disease Questionnaire (IBDQ) questionnaire score)
Tidsram: Up to Week 20
|
Change from Baseline in Subjects' Quality of Life based on the IBDQ questionnaire score at Week 10 and Week 20
|
Up to Week 20
|
|
The number of subjects with adverse events
Tidsram: From screening up to 2 weeks after last dose
|
To evaluate the safety and tolerability of GLPG0634 in comparison with placebo in terms of adverse events (AEs)
|
From screening up to 2 weeks after last dose
|
|
The number of subjects with abnormal lab tests
Tidsram: From screening up to 2 weeks after last dose
|
To evaluate the safety and tolerability of GLPG0634 in comparison with placebo in terms laboratory test abnormalities
|
From screening up to 2 weeks after last dose
|
|
The number of subjects with abnormal vital signs
Tidsram: From screening up to 2 weeks after last dose
|
To evaluate the safety and tolerability of GLPG0634 in comparison with placebo in terms of abnormalities in vital signs
|
From screening up to 2 weeks after last dose
|
|
The number of subjects with abnormal ECG
Tidsram: From screening up to 2 weeks after last dose
|
To evaluate the safety and tolerability of GLPG0634 in comparison with placebo in terms of abnormalities in electrocardiogram (ECG)
|
From screening up to 2 weeks after last dose
|
|
The plasma levels of GLPG0634 and its metabolite
Tidsram: Up to Week 20
|
To characterize the pharmacokinetics (PK) of GLPG0634 and its metabolite by measuring the amount in plasma from Week 2 up to Week 20 at every visit
|
Up to Week 20
|
|
The change versus Baseline in levels of immune- and inflammation-related parameters in whole blood and serum
Tidsram: Up to Week 20
|
To characterize the pharmacodynamics (PD) of GLPG0634 and its metabolite by measuring the levels of immune- and inflammation-related parameters in whole blood and serum
|
Up to Week 20
|
|
The change versus Baseline in levels of faecal calprotectin
Tidsram: Up to Week 20
|
To characterize the pharmacodynamics (PD) of GLPG0634 and its metabolite by measuring the levels of faecal calprotectin
|
Up to Week 20
|
|
The change versus Baseline in microbial communities in stool samples
Tidsram: Up to Week 10
|
To characterize the effects of GLPG0634 and its metabolite on the microbial communities by measuring the levels of predominant microbiota in stool samples
|
Up to Week 10
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Utredare
- Studierektor: Pille Harrison, MD, Galapagos NV
Publikationer och användbara länkar
Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 februari 2014
Primärt slutförande (Faktisk)
1 november 2015
Avslutad studie (Faktisk)
1 februari 2016
Studieregistreringsdatum
Först inskickad
27 januari 2014
Först inskickad som uppfyllde QC-kriterierna
27 januari 2014
Första postat (Uppskatta)
29 januari 2014
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
23 februari 2016
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
21 februari 2016
Senast verifierad
1 februari 2016
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- GLPG0634-CL-211
- 2013-002857-32 (EudraCT-nummer)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .